Main Page


Revision as of 16:10, 4 March 2018 by Officeloan9 (Talk | contribs)
Jump to: navigation, search

vol. 27, no. 2, pp. 124-139, Summer season 2009. [36] M. B m Ease" Cardiovasc. Ther. vol. 27, no. two, pp. 124-139, Summer season 2009. [36] M. B m, R.H. 02699931.2015.1049516 Schwinger, E. Erdmann, "Different cardiodepressant potency of various calcium antagonists in human myocardium" Am. J. Cardiol. vol. 65, no. 15, pp. 1039-41, Apr. 1990. [37] C.J. Maxwell, D.B. Hogan , N.R. Campbell , E.M. Ebly "Nifedipine and mortality risk within the elderly: relevance of drug formulation, dose and duration" Pharmacoepidemiol Drug Saf. vol. 9, no. 1, pp. 11-23, Jan. 2000. [38] S.Y. Jung, N.K. Choi, J.Y. Kim, Y. Chang, H.J. Song, J. Lee, B.J.Park, "Short-acting nifedipine and risk of stroke in elderly hypertensive patients" Neurology vol. 77, no. 13, pp. 1229-1234, Sep 2011. [39] K. Aouam, A. Berdeaux, "Dihydropyridines from the very first towards the fourth generation: greater effects and safety" Therapie vol. 58, no. four, pp. 333-339, Jul-Aug 2003. [40] T. Toyo-oka, W.G. Nayler, "Third generation calcium entry blockers" Blood Press vol. five, no. 4, pp. 206?08, Jul. 1996. [41] K.W. Kenyon, "Clevidipine: an ultra shortacting calcium channel antagonist for acute hypertension" Ann. Pharmacother. vol. 43, no. 7, pp. 1258-1265, Jul. 2009. [42] I.M. Espina, J. Varon, "Clevidipine : a stateof-the-art antihypertensive drug below the scope" Professional. Opin. Pharmacother. vol. 13, no. 3, pp. 387-393, Feb. 2012. [43] A.S. Awad, M.E. Goldberg, "Role of clevidipine butyrate inside the treatment of acute hypertension within the crucial care setting: a evaluation. Vasc. Wellness Threat. Manag. vol. six, pp. 457-464,Aug. 2010. [44] M.E. Williams, D.H. Feldman, A.F. McCue, R. Brenner, G. Velicelebi, S.B. Ellis, M.M. Harpold "Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype" Neuron vol. 8, no. 1, pp. 71-84, Jan. 1992. [45] K.Takimoto, D. Li, J.M. Nerbonne, and E.S. Levitan, "Distribution, splicing and glucocorticoidinduced expression of cardiac alpha 1C and alpha 1D voltage-gated Ca2+ channel mRNAs" J. Mol. Cell. Cardiol. vol. 29, no. 11, pp. 3035?042, Nov. 1997.[46] Platzer J, Engel J, Schrott-Fischer A, Stephan K, Bova S, Chen H, Zheng H, J. Striessnig, "Congenital deafness and sinoatrial node dysfunction in mice lacking class D L-type Ca2+ channels" Cell vol. 102, no. 1, pp. 8997, Jul. 2000. [47] A.Koschak, D. Reimer, I. Huber, M. Grabner, H. Glossmann, J. Engel, J. Striessnig, "alpha 1D (Cav1.3) subunits can form L-type Ca2+ channels activating at negative voltages" J. Biol. Chem. vol. 276, no. 25, pp. 22100-22106, June 2001. [48] A. Zuccotti, S. Clementi, T. Reinbothe, A. Torrente, D.H. Vandael, A. Pirone, "Structural and functional variations involving L-type calcium channels: important troubles for future selective targeting. Trends Pharmacol. Sci. vol. 32, no. 6, pp. 366-375, Jun. 2011. [49] Z. Zhang, Y. He, fnins.2013.00251 D. Tuteja, D. Xu, V. Timofeyev, Q. Zhang, K.A. Glatter, Y. Xu, H.S. Shin, R. Low, N. Chiamvimonvat, "Functional roles of Cav1.three(alpha1D) calcium channels in atria: insights gained from gene-targeted null mutant mice" Circulation vol.

Personal tools